VEGFA and osteosarcoma: Despite the absence of prognostic impact of VEGF levels in our study, encouraging tumour responses obtained with anti-angiogenic agents in experimental osteosarcoma models, phase II clinical trials, and case reports [37–39] suggest that angiogenesis could play a major role in osteosarcoma progression.